160 related articles for article (PubMed ID: 18075315)
1. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
2. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
3. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
6. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
7. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
8. Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors.
Siffroi-Fernandez S; Dulong S; Li XM; Filipski E; Gréchez-Cassiau A; Peteri-Brünback B; Meijer L; Lévi F; Teboul M; Delaunay F
Cell Cycle; 2014; 13(6):984-91. PubMed ID: 24552823
[TBL] [Abstract][Full Text] [Related]
9. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
[TBL] [Abstract][Full Text] [Related]
10. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
11. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
12. Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib.
Iurisci I; Filipski E; Sallam H; Harper F; Guettier C; Maire I; Hassan M; Iacobelli S; Lévi F
Chronobiol Int; 2009 Aug; 26(6):1169-88. PubMed ID: 19731111
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo.
McClue SJ; Stuart I
Drug Metab Dispos; 2008 Mar; 36(3):561-70. PubMed ID: 18048486
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance.
Khalil HS; Mitev V; Vlaykova T; Cavicchi L; Zhelev N
J Biotechnol; 2015 May; 202():40-9. PubMed ID: 25747275
[TBL] [Abstract][Full Text] [Related]
15. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis.
Sheryanna AM; Smith J; Bhangal G; Barnett A; McClue S; Tam FW; Cook T; Pusey CD
Nephrology (Carlton); 2011 May; 16(4):410-6. PubMed ID: 21518118
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
17. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
[TBL] [Abstract][Full Text] [Related]
18. Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.
McNeely SC; Taylor BF; States JC
Toxicol Appl Pharmacol; 2008 Aug; 231(1):61-7. PubMed ID: 18501396
[TBL] [Abstract][Full Text] [Related]
19. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes.
Atanasova G; Jans R; Zhelev N; Mitev V; Poumay Y
Biochem Pharmacol; 2005 Sep; 70(6):824-36. PubMed ID: 16011834
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
